Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011302075> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W3011302075 endingPage "671" @default.
- W3011302075 startingPage "669" @default.
- W3011302075 abstract "Herpes zoster (HZ) incidence is higher in patients with rheumatoid arthritis (RA) compared with the general population,1 and it may be further increased with disease-modifying antirheumatic drugs (DMARDs).2 Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Real-world data indicate that HZ incidence is approximately twofold higher with tofacitinib versus biologic DMARDs (bDMARDs).3 Current American College of Rheumatology guidelines conditionally recommend that patients with RA aged ≥50 years receive HZ vaccine prior to tofacitinib or bDMARDs.4 We previously evaluated the immunogenicity of a live attenuated zoster vaccine (LZV), administered 2–3 weeks prior to tofacitinib or placebo with background conventional synthetic DMARDs. Both groups had similar varicella zoster virus (VZV)-specific immune responses, and overall immune responses were comparable with those of healthy volunteers in previous studies.5 We have now followed this patient cohort in an open-label, long-term extension (LTE) study of tofacitinib.Patients enrolled in the index study (A3921237; NCT02147587)5 could join ORAL Sequel (LTE study; A3921024; NCT00413699) 14 weeks post-vaccination, where they received open-label tofacitinib 5 or 10 mg two times per day (online supplementary figure S1); background RA therapy was also allowed. Patients were followed for 27 months. Post-vaccination, adverse events (AEs), including discontinuations due to AEs, were recorded during the study within 28 days of …" @default.
- W3011302075 created "2020-03-23" @default.
- W3011302075 creator A5006070255 @default.
- W3011302075 creator A5006742120 @default.
- W3011302075 creator A5016518147 @default.
- W3011302075 creator A5025867925 @default.
- W3011302075 creator A5027752564 @default.
- W3011302075 creator A5062789852 @default.
- W3011302075 creator A5075200726 @default.
- W3011302075 creator A5083583562 @default.
- W3011302075 creator A5089961811 @default.
- W3011302075 creator A5090208499 @default.
- W3011302075 date "2020-03-11" @default.
- W3011302075 modified "2023-10-16" @default.
- W3011302075 title "Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib" @default.
- W3011302075 cites W2142004396 @default.
- W3011302075 cites W2147014650 @default.
- W3011302075 cites W2297608701 @default.
- W3011302075 cites W2343866616 @default.
- W3011302075 cites W2749941863 @default.
- W3011302075 doi "https://doi.org/10.1136/annrheumdis-2019-216566" @default.
- W3011302075 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7213307" @default.
- W3011302075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32161057" @default.
- W3011302075 hasPublicationYear "2020" @default.
- W3011302075 type Work @default.
- W3011302075 sameAs 3011302075 @default.
- W3011302075 citedByCount "11" @default.
- W3011302075 countsByYear W30113020752020 @default.
- W3011302075 countsByYear W30113020752021 @default.
- W3011302075 countsByYear W30113020752022 @default.
- W3011302075 countsByYear W30113020752023 @default.
- W3011302075 crossrefType "journal-article" @default.
- W3011302075 hasAuthorship W3011302075A5006070255 @default.
- W3011302075 hasAuthorship W3011302075A5006742120 @default.
- W3011302075 hasAuthorship W3011302075A5016518147 @default.
- W3011302075 hasAuthorship W3011302075A5025867925 @default.
- W3011302075 hasAuthorship W3011302075A5027752564 @default.
- W3011302075 hasAuthorship W3011302075A5062789852 @default.
- W3011302075 hasAuthorship W3011302075A5075200726 @default.
- W3011302075 hasAuthorship W3011302075A5083583562 @default.
- W3011302075 hasAuthorship W3011302075A5089961811 @default.
- W3011302075 hasAuthorship W3011302075A5090208499 @default.
- W3011302075 hasBestOaLocation W30113020751 @default.
- W3011302075 hasConcept C159654299 @default.
- W3011302075 hasConcept C16005928 @default.
- W3011302075 hasConcept C203014093 @default.
- W3011302075 hasConcept C2777575956 @default.
- W3011302075 hasConcept C2778886723 @default.
- W3011302075 hasConcept C2779605438 @default.
- W3011302075 hasConcept C2780653079 @default.
- W3011302075 hasConcept C71924100 @default.
- W3011302075 hasConceptScore W3011302075C159654299 @default.
- W3011302075 hasConceptScore W3011302075C16005928 @default.
- W3011302075 hasConceptScore W3011302075C203014093 @default.
- W3011302075 hasConceptScore W3011302075C2777575956 @default.
- W3011302075 hasConceptScore W3011302075C2778886723 @default.
- W3011302075 hasConceptScore W3011302075C2779605438 @default.
- W3011302075 hasConceptScore W3011302075C2780653079 @default.
- W3011302075 hasConceptScore W3011302075C71924100 @default.
- W3011302075 hasIssue "5" @default.
- W3011302075 hasLocation W30113020751 @default.
- W3011302075 hasLocation W30113020752 @default.
- W3011302075 hasLocation W30113020753 @default.
- W3011302075 hasLocation W30113020754 @default.
- W3011302075 hasLocation W30113020755 @default.
- W3011302075 hasOpenAccess W3011302075 @default.
- W3011302075 hasPrimaryLocation W30113020751 @default.
- W3011302075 hasRelatedWork W1984540686 @default.
- W3011302075 hasRelatedWork W2315545909 @default.
- W3011302075 hasRelatedWork W2503659988 @default.
- W3011302075 hasRelatedWork W2906724980 @default.
- W3011302075 hasRelatedWork W2929695502 @default.
- W3011302075 hasRelatedWork W3001590743 @default.
- W3011302075 hasRelatedWork W3015942815 @default.
- W3011302075 hasRelatedWork W3035443521 @default.
- W3011302075 hasRelatedWork W3118952277 @default.
- W3011302075 hasRelatedWork W4247961006 @default.
- W3011302075 hasVolume "79" @default.
- W3011302075 isParatext "false" @default.
- W3011302075 isRetracted "false" @default.
- W3011302075 magId "3011302075" @default.
- W3011302075 workType "article" @default.